Pavlov-Dolijanovic S, et al. - Authors evaluated the impacts of induction treatment with cyclophosphamide (CYC) pulse therapy followed by maintenance treatment with other mild immunosuppressive agents on lung function in scleroderma (SSc) patients. They included 30 patients with SSc (mean age 52 years, mean disease duration < 2 years) with forced vital capacity (FVC) ≤ 80% and/or diffusing capacity of carbon monoxide (DLco) ≤ 70%. Findings did not suggest a significant difference in mean FVC and DLco changes from baseline values. Clinically significant improvement of pulmonary function was not seen with CYC, however, it fulfilled criteria of stable disease. The benefits achieved during CYC treatment were preserved by the maintenance treatment with other mild immunosupressive agents.